Strategy+ is advising one of the world’s premier biopharmaceutical companies Pfizer (NYSE: PFE) on the acquisition of Therachon Holding AG, a privately-held clinical-stage biotechnology company focused on rare disease. The definitive agreement was announced May 8, 2019. Pfizer will acquire Therachon for $340 Million upfront with an additional $470 Million in additional payments contingent on the achievement of key milestones.
Note to Editors: This press release may contain forward-looking statements regarding Strategy+’s intentions and interests. These statements are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results may differ materially from those expressed or implied in these statements. The firm does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
